Table 4.
Clinical trials of targeted neutrophil therapies for cancers
| Targets | Agents | Cancer applications | Phase | NCT trial number | Treatment regimen | References |
|---|---|---|---|---|---|---|
| CXCR1/CXCR2 | Navarixin (MK-7123) | Solid tumor | II | NCT03473925 | Navarixin + Pembrolizumab | NA |
| SX-682 (BKT140) | Resectable pancreatic cancer | II | NCT05604560 | SX-682 + Tislelizumab | NA | |
| Reparixin | Metastatic triple-negative breast cancer | II | NCT02370238 | Reparixin + Paclitaxel | NA | |
| AZD5069 | Metastatic castration-resistant prostate cancer | I/II | NCT03177187 | AZD5069 + Enzalutamide | NA | |
| IL-8 | BMS-986253 | Hepatocellular carcinoma | II | NCT04050462 | BMS-986253 + Nivolumab | NA |
| C5aR | IPH5401 | Solid tumor | I | NCT03665129 | IPH5401 + Durvalumab | NA |
| TJ210001 | Solid tumor | I | NCT04947033 | Monotherapy | NA | |
| CD47-SIRPα | Magrolimab | TP53 mutant acute myeloid leukemia | III | NCT04778397 | Magrolimab + Azacitidine | [142] |
| Lemzoparlimab | Refractory non-Hodgkin’s lymphoma | Ib | NCT03934814 | Lemzoparlimab + Rituximab | [143] | |
| CC-95251 | Relapsed and/or refractory non-Hodgkin lymphoma | I | NCT03783403 | CC-95251 + Rituximab | [144] | |
| BI 765063 | Solid tumors | I | NCT03990233 | BI 765063 + BI 754091 | [145] | |
| STAT3 | TTI-101 | Recurrent or metastatic head and neck squamous cell carcinoma | I/II | NCT05668949 | TTI-101 + Pembrolizumab | NA |
| Napabucasin | Metastatic colorectal cancer | III | NCT02753127 | BBI-608 + FOLFIRI (5-Fluorouracil, Leucovorin, Irinotecan) | [146] | |
| AZD9150 (Danvatirsen) | Advanced pancreatic cancer, non-small cell lung cancer, and mismatch repair deficient colorectal cancer | II | NCT02983578 | AZD9150 + MEDI4736 | NA | |
| TGF-β | LY2157299 | Locally advanced rectal adenocarcinoma | II | NCT02688712 | LY2157299 + Neoadjuvant chemoradiation | [147] |
| M7824 (bintrafusp alfa) | Non-small cell lung cancer | III | NCT03631706 | Monotherapy | NA | |
| NIS793 | Metastatic pancreatic ductal adenocarcinoma | III | NCT04935359 | NIS793 + Nab-paclitaxel/gemcitabine | [148] | |
| G-CSF | Efbemalenograstim alfa (F-627) | Breast cancer | III | NCT04174599 | Monotherapy | [149] |
| IL-6 | Tocilizumab | Melanoma | II | NCT03999749 | Tocilizumab + Ipilimumab and Nivolumab | [150] |
| Siltuximab | High-risk smoldering multiple myeloma | II | NCT01484275 | Monotherapy | [151] |